# David R. Spriggs

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/david-r-spriggs/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,504 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 71 |
| i10-index | 187 |
| Last Known Institution | Harvard University |
| OpenAlex ID | https://openalex.org/A5073323475 |
| ORCID iD | https://orcid.org/0000-0003-2174-4992 |
| Works | 425 |

## Researcher papers

- [Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial](https://scholariq.org/papers/gemcitabine-and-docetaxel-in-patients-with-unresectable-leiomyosarcoma-results/)
- [A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer](https://scholariq.org/papers/a-phase-i-clinical-trial-of-adoptive-t-cell-therapy-using-il-12-secreting-muc/)
- [Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer](https://scholariq.org/papers/clinical-utility-of-prospective-molecular-characterization-in-advanced/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Statistical Methods in Clinical Trials](https://scholariq.org/topics/statistical-methods-in-clinical-trials/)

## Researcher university

- [Harvard University](https://scholariq.org/institutions/harvard-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.